Captor Therapeutics Spolka Akcyjna

Warsaw Stock Exchange CTX.WA

Captor Therapeutics Spolka Akcyjna Return on Equity (ROE) for the year ending December 31, 2023: -101.97%

Captor Therapeutics Spolka Akcyjna Return on Equity (ROE) is -101.97% for the year ending December 31, 2023, a -193.86% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Captor Therapeutics Spolka Akcyjna Return on Equity (ROE) for the year ending December 31, 2022 was -34.70%, a -30.71% change year over year.
Captor Therapeutics Spolka Akcyjna Return on Equity (ROE) for the year ending December 31, 2021 was -26.55%, a -102.04% change year over year.
Captor Therapeutics Spolka Akcyjna Return on Equity (ROE) for the year ending December 31, 2020 was 1,303.49%, a 738.31% change year over year.
Captor Therapeutics Spolka Akcyjna Return on Equity (ROE) for the year ending December 31, 2019 was -204.21%, a -58.44% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Warsaw Stock Exchange: CTX.WA

Captor Therapeutics Spolka Akcyjna

CEO	Dr. Thomas Shepherd Ph.D.
IPO Date	April 1, 2021
Location	Poland
Headquarters	ul. Dunska 11
Employees	105
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.

Key trends

Past 5 years